Your new post is loading...
B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients.
Via Krishan Maggon
|
Scooped by Gilbert C FAURE from Multiple sclerosis New Drugs Review |
Scoop.it!
Via Krishan Maggon
Acta Neuropathol Commun. 2014 Sep 16;2:138. doi: 10.1186/s40478-014-0138-2.Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood.Hohmann C, Milles B, Schinke M, Schroeter M, Ulzheimer J, Kraft P, Kleinschnitz C, Lehmann PV, Kuerten S.
Acta Neuropathologica Communications 2014, 2:138 doi:10.1186/s40478-014-0138-2
The electronic version of this article is the complete one and can be found online at:http://www.actaneurocomms.org/content/2/1/138
Received:17 July 2014Accepted:5 September 2014Published:16 September 2014
© 2014 Hohmann et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.